Pharmacy Department, Indiana University Health, Indianapolis, IN, USA.
Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA.
Pharmacogenomics. 2022 Jun;23(9):559-556. doi: 10.2217/pgs-2022-0025. Epub 2022 Jun 7.
Cystic fibrosis is a genetic, multiorgan system disease that involves the use of many medications to control symptoms associated with the underlying condition. Many of these medications have Clinical Pharmacogenetics Implementation Consortium evidence-based guidelines for pharmacogenomics that are available to guide dosing. The aim of this article is to review relevant literature and evaluate the utility of preemptive pharmacogenomics testing for persons with cystic fibrosis and propose a pharmacogenomics panel that could be considered standard of care for persons with cystic fibrosis.
囊性纤维化是一种遗传的多器官系统疾病，需要使用多种药物来控制与基础疾病相关的症状。这些药物中有许多都有临床药物基因组学实施联盟基于证据的药物基因组学指导原则，可用于指导剂量。本文的目的是回顾相关文献，评估对囊性纤维化患者进行预先药物基因组学检测的效用，并提出一个可被视为囊性纤维化患者标准护理的药物基因组学检测面板。
